ArticleEmerging infectious diseases2019
Molecular and Clinical Comparison of Enterovirus D68 Outbreaks among Hospitalized Children, Ohio, USA, 2014 and 2018.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence and case fatality rate of Enterovirus D68 infections, a systematic review and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Salt-inducible kinase 1 is a key gene in suppressing EVD68-induced asthma by modulating antiviral immunity.Genes & diseases · 2026Article
- Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.Emerging infectious diseases · 2026Review
- Molecular characterization of enteroviruses in patients with acute respiratory infection and influenza-like illness in the Central African Republic revealed mainly polioviruses and other enteric enterovirus types.Access microbiology · 2026Article
- Global Prevalence of Non-Polio Enteroviruses Pre- and Post COVID-19 Pandemic.Microorganisms · 2025Review
- Identification of four neutralizing antigenic sites on the enterovirus D68 capsid.Journal of virology · 2023Article
- First Detection of Enterovirus D68 in Korean Children, September 2022.Infection & chemotherapy · 2023Article
- Clinical and molecular epidemiologic features of enterovirus D68 infection in children with acute lower respiratory tract infection in China.Archives of virology · 2023Review
- Bacterial ribosomal RNA detection in cerebrospinal fluid using a viromics approach.Fluids and barriers of the CNS · 2022Article
- Enterovirus D68 epidemic, UK, 2018, was caused by subclades B3 and D1, predominantly in children and adults, respectively, with both subclades exhibiting extensive genetic diversity.Microbial genomics · 2022Article
- Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA.Emerging infectious diseases · 2022Article
- Article
- Epidemiological dynamics of enterovirus D68 in the US: implications for acute flaccid myelitis.medRxiv : the preprint server for health sciences · 2021Article
- Biennial Upsurge and Molecular Epidemiology of Enterovirus D68 Infection in New York, USA, 2014 to 2018.Journal of clinical microbiology · 2020Article
- The importance of viral testing in infants and young children with bronchiolitis.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus D68 (EV-D68) causes respiratory tract infections and neurologic manifestations. We compared the clinical manifestations from 2 EV-D68 outbreaks in 2014 and 2018 and a low-activity period in 2016 among hospitalized children in central Ohio, USA, and used PCR and sequencing to enable phylogenetic comparisons. During both outbreak periods, infected children had respiratory manifestations that led to an increase in hospital admissions for asthma. The 2018 EV-D68 outbreak appeared to be milder in terms of respiratory illness, as shown by lower rates of pediatric intensive care unit admission. However, the frequency of severe neurologic manifestations was higher in 2018 than in 2014. During the same period in 2016, we noted neither an increase in EV-D68 nor a significant increase in asthma-related admissions. Phylogenetic analyses showed that EV-D68 isolates from 2018 clustered differently within clade B than did isolates from 2014 and are perhaps associated with a different EV-D68 subclade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.